Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 Years — United States, January–March 2021

Wallace, Megan; Woodworth, Kate R.; Gargano, Julia W.; Scobie, Heather M.; Blain, Amy E.; Moulia, Danielle; Chamberland, Mary; Reisman, Nicole; Hadler, Stephen C.; MacNeil, Jessica R.; Campos-Outcalt, Doug; Morgan, Rebecca L.; Daley, Matthew F.; Romero, José R.; Talbot, H. Keipp; Lee, Grace M.; Bell, Beth P.; Oliver, Sara E.

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 Years — United States, January–March 2021

May 14, 2021
By Wallace, Megan ; Woodworth, Kate R. ; Gargano, Julia W. ; ...
Series: MMWR. Morbidity and mortality weekly report ; v. 70, early release, May 14, 2021

[PDF-324.04 KB]

English

Details Supporting Files Related Documents You May Also Like

Details:

Personal Author:

Wallace, Megan ; Woodworth, Kate R. ; Gargano, Julia W. ; Scobie, Heather M. ; Blain, Amy E. ; ... More +

Wallace, Megan ; Woodworth, Kate R. ; Gargano, Julia W. ; Scobie, Heather M. ; Blain, Amy E. ; Moulia, Danielle ; Chamberland, Mary ; Reisman, Nicole ; Hadler, Stephen C. ; MacNeil, Jessica R. ; Campos-Outcalt, Doug ; Morgan, Rebecca L. ; Daley, Matthew F. ; Romero, José R. ; Talbot, H. Keipp ; Lee, Grace M. ; Bell, Beth P. ; Oliver, Sara E. Less -
Corporate Authors:

United States. Advisory Committee on Immunization Practices. ; CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. ; University of Arizona. College of Medicine. ; McMaster University. Faculty of Health Sciences. Department of Health Research Methods, Evidence, and Impact. ; ... More +

United States. Advisory Committee on Immunization Practices. ; CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. ; University of Arizona. College of Medicine. ; McMaster University. Faculty of Health Sciences. Department of Health Research Methods, Evidence, and Impact. ; Kaiser Permanente Colorado. Institute for Health Research. ; Arkansas. Department of Health. ; Vanderbilt University School of Medicine. ; Stanford University School of Medicine. ; University of Washington. Less -
Description:

What is already known about this topic? On May 10, 2021, the Food and Drug Administration expanded Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12–15 years.

What is added by this report? On May 12, 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years for the prevention of COVID-19.

What are the implications for public health practice? The Pfizer-BioNTech COVID-19 vaccine is the first COVID-19 vaccine approved for use in adolescents and has high efficacy against symptomatic COVID-19. Vaccination will be important to protect adolescents against symptomatic COVID-19 disease and to reduce community transmission of SARS-CoV-2.

The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine (Pfizer, Inc; Philadelphia, Pennsylvania) in persons aged ≥16 years (1); on December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the vaccine in the same age group (2). As of May 12, 2021, approximately 141.6 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥16 years.* On May 10, 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12–15 years (1). On May 12, 2021, ACIP issued an interim recommendation† for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework,§ using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥12 years under an EUA is interim and will be updated as additional information becomes available.

Suggested citation for this article: Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021. MMWR Morb Mortal Wkly Rep. ePub: 14 May 2021.

mm7020e1.htm?s_cid=mm7020e1_w
Subjects:

[+]

Adolescent Advisory Committees Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Drug Approval Immunization/standards Vaccination Viral Vaccines
Series:

MMWR. Morbidity and mortality weekly report ; v. 70, early release, May 14, 2021
Document Type:

Journal Article
Name as Subject:

Pfizer-BioNTech COVID-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine

Pfizer-BioNTech COVID-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine Less -
Place as Subject:

United States
Location:

North America
Pages in Document:

4 numbered pages
Volume:

70
Collection(s):

Morbidity and Mortality Weekly Report (MMWR) Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:

[+]

urn:sha256:5d6421b008243dc6effc1c4a86c0f1a078ebe99567937deadb5a951acc125248
Download URL:

https://stacks.cdc.gov/view/cdc/106198/cdc_106198_DS1.pdf
File Type:

mm7020e1.htm

htm

More +